Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...
With the rise in global counterfeiting operations, stakeholders need to be aware of their responsibility when it comes to pharmaceutical goods and their legitimacy. Companies can make this task easier ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
THURSDAY, Nov. 7, 2024 (HealthDay News) -- The head of the company that makes the diabetes and obesity drugs Ozempic and ...
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted ...
The departure comes as the heavily-backed telehealth company navigates growing pains at home and focuses on stability and ...
Astra saw £14.4bn wiped off its value after Chinese media said dozens of managers were implicated in a scandal.
Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback